T1	Participants 42 133	employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo
T2	Participants 319 373	employed patients with major depressive disorder (MDD)
T3	Participants 383 561	Gainfully employed (≥20 h/wk) male and female outpatients with MDD were randomly assigned (2:1 ratio) to 12 weeks of double-blind treatment with desvenlafaxine 50 mg/d or placebo
T4	Participants 841 957	A predefined, modified ITT population (ie, those in the ITT population with baseline HAM-D₁₇ ≥20) was also analyzed.
T5	Participants 1849 1881	MDD in gainfully employed adults
